SOURCE: NuLife Sciences, Inc.

NuLife Sciences, Inc. Logo

August 23, 2017 07:30 ET

NuLife to Present at the 2017 Southern California Investor Conference

NEWPORT BEACH, CA--(Marketwired - August 23, 2017) - NuLife Sciences (OTCQB: NULF) today announced that management will attend the 2017 Southern California Investor Conference in Newport Beach, CA on Thursday, August 24, 2017.

NuLife will host one-on-one meetings throughout the day and is scheduled to present as follows:

2017 Southern California Investor Conference
Date: Thursday, August 24, 2017
Presentation Time: 12:30 p.m. Pacific time
Location: The Island Hotel, 690 Newport Center Drive, Newport Beach, CA (Track 1)

Conference participation is by invitation only and registration is mandatory. For more information on the conference, please visit the conference website.

About the Southern California Investor Conference

The Southern California Investor Conference is the premier investor conference highlighting growth companies from the region. Over its 20-year history, the conference has featured many of the leading growth and emerging companies originating exclusively from Southern California. The 2017 Southern California Investor Conference will be held on August 24th at the Island Hotel in Newport Beach, CA. For more information, please visit www.SCIC2017.com or call (858) 335-3134.

About NuLife Sciences

NuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation, regenerative medicine, cell therapy, organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal studies on its pathway to commercialization. For more information please visit www.nulifesciences.us.

Contact Information